Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $139,781.90 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. The trade was a 3.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Apellis Pharmaceuticals Price Performance

Shares of APLS opened at $25.04 on Friday. The stock has a market cap of $3.11 billion, a PE ratio of -12.33 and a beta of 0.93. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $23.77 and a fifty-two week high of $63.07. The firm’s 50-day simple moving average is $29.08 and its two-hundred day simple moving average is $31.07.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.73) earnings per share. Analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Wedbush decreased their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Royal Bank of Canada reduced their price target on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research report on Monday, March 3rd. JPMorgan Chase & Co. boosted their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Morgan Stanley began coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target on the stock. Finally, The Goldman Sachs Group reduced their price target on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $45.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in shares of Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth approximately $824,000. BNP Paribas Financial Markets lifted its stake in shares of Apellis Pharmaceuticals by 52.9% in the third quarter. BNP Paribas Financial Markets now owns 159,700 shares of the company’s stock worth $4,606,000 after buying an additional 55,282 shares in the last quarter. Old West Investment Management LLC bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth approximately $2,953,000. Finally, KBC Group NV lifted its stake in shares of Apellis Pharmaceuticals by 3,862.3% in the fourth quarter. KBC Group NV now owns 104,287 shares of the company’s stock worth $3,328,000 after buying an additional 101,655 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).